Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.2% during the fourth quarter, Holdings Channel reports. The fund owned 10,302 shares of the biopharmaceutical company’s stock after purchasing an additional 2,006 shares during the quarter. Wealthfront Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $2,507,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ALNY. Allworth Financial LP boosted its stake in Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 38 shares during the last quarter. Nixon Peabody Trust Co. boosted its stake in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares during the last quarter. Huntington National Bank boosted its stake in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. IFP Advisors Inc boosted its stake in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 47 shares during the last quarter. Finally, Nwam LLC boosted its stake in Alnylam Pharmaceuticals by 5.8% in the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Sanford C. Bernstein decreased their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. HC Wainwright raised their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a “neutral” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $241.76 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The stock’s 50 day moving average is $255.02 and its two-hundred day moving average is $260.44. The company has a market capitalization of $31.30 billion, a PE ratio of -111.41 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.